Previous Article | Next Article 
Mol Cell Biol, May 1998, p. 3044-3058, Vol. 18, No. 5
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Activation of Rho-Dependent Cell Spreading and
Focal Adhesion Biogenesis by the v-Crk Adaptor Protein
Zeynep F.
Altun-Gultekin,1,
Sanjay
Chandriani,2
Cecile
Bougeret,2
Toshimasa
Ishizaki,3
Shuh
Narumiya,3
Petra
de
Graaf,4
Paul
Van Bergen
en Henegouwen,4
Hidesaburo
Hanafusa,2
John A.
Wagner,1 and
Raymond
B.
Birge2,*
Department of Neurology and Neuroscience,
Cornell University Medical College,1 and
Laboratory of Molecular Oncology, The Rockefeller
University,2 New York, New York;
Second
Department of Pharmacology, Faculty of Medicine, Kyoto University,
Kyoto, Japan3; and
Department of
Molecular Cell Biology, Utrecht University, Utrecht, The
Netherlands4
Received 1 October 1997/Returned for modification 12 November
1997/Accepted 2 February 1998
 |
ABSTRACT |
The small GTPase RhoA plays a critical role in signaling pathways
activated by serum-derived factors, such as lysophosphatidic acid
(LPA), including the formation of stress fibers in fibroblasts and
neurite retraction and rounding of soma in neuronal cells. Previously,
we have shown that ectopic expression of v-Crk, an SH2/SH3
domain-containing adapter proteins, in PC12 cells potentiates nerve
growth factor (NGF)-induced neurite outgrowth and promotes the survival
of cells when NGF is withdrawn. In the present study we show that, when
cultured in 15% serum or lysophosphatidic acid-containing medium, the
majority of v-Crk-expressing PC12 cells (v-CrkPC12 cells) display a
flattened phenotype with broad lamellipodia and are refractory to
NGF-induced neurite outgrowth unless serum is withdrawn. v-Crk-mediated
cell flattening is inhibited by treatment of cells with C3 toxin or by
mutation in the Crk SH2 or SH3 domain. Transient cotransfection of 293T
cells with expression plasmids for p160ROCK (Rho-associated
coiled-coil-containing kinase) and v-Crk, but not SH2 or SH3 mutants of
v-Crk, results in hyperactivation of p160ROCK. Moreover,
the level of phosphatidylinositol-4,5-bisphosphate is increased in
v-CrkPC12 cells compared to the levels in mutant v-Crk-expressing cells
or wild-type cells, consistent with PI(4)P5 kinase being a downstream
target for Rho. Expression of v-Crk in PC12 cells does not result in
activation of Rac- or Cdc42-dependent kinases PAK and S6 kinase,
demonstrating specificity for Rho. In contrast to native PC12 cells, in
which focal adhesions and actin stress fibers are not observed,
immunohistochemical analysis of v-CrkPC12 cells reveals focal adhesion
complexes which are formed at the periphery of the cell and are
connected to actin cables. The formation of focal adhesions correlates
with a concomitant upregulation in the expression of focal adhesion
proteins FAK, paxillin,
3-integrin, and a
higher-molecular-weight form of
1-integrin. Our results
indicate that v-Crk activates the Rho-signaling pathway and serves as a
scaffolding protein during the assembly of focal adhesions in PC12
cells.
 |
INTRODUCTION |
Various cellular functions such as
cell motility, cell survival, cytokinesis, and neurite outgrowth are
dependent on temporal and spatial reorganization of the actin
cytoskeleton. Rearrangement of the actin cytoskeleton results from
signals activated by soluble factors (inside-out signals) and
cell-substratum and cell-cell adhesion molecules (outside-in signals).
In cultured cells, integration of these signals takes place in the
focal adhesions (58) which are associated with well-defined
actin stress fibers and provide tight binding to the underlying
extracellular matrix. These contractile stress fibers are postulated to
exert tension on the substratum and to play a role in morphogenesis and
regulate cell motility.
Actin stress fibers and focal adhesions form in quiescent fibroblasts
in response to microinjection of constitutively active Rho GTPase or by
extracellular signals such as lysophosphatidic acid (LPA) and bombesin
(62) which lead to the activation of Rho. ADP-ribosylation
and inhibition of Rho by Clostridium botulinum C3 toxin
prevent this process. During focal adhesion assembly, several
adhesion-associated proteins, including focal adhesion kinase (FAK),
paxillin, and p130cas, become tyrosine
phosphorylated, suggesting the involvement of a tyrosine
phosphorylation cascade in this event (9, 65, 77).
LPA-induced activation of Rho can be blocked by an inhibitor of
tyrosine kinase signaling, tryphostin, suggesting that tyrosine kinases
act upstream of Rho activation (57). However, it has also
been demonstrated that introduction of activated Rho into cells induces
tyrosine phosphorylation of FAK, paxillin, and
p130cas, placing tyrosine kinases downstream of
Rho (18). To further support this concept, another tyrosine
kinase inhibitor, genistein, prevents the formation of stress fibers
after microinjection of constitutively active Rho (61).
Besides serum-derived factors, binding of integrins to extracellular
matrix proteins also activates Rho and induces stress fiber formation
in the absence of serum (4). It is currently not well
understood how integrin engagement, tyrosine kinase signaling, Rho
activation, and formation of focal adhesions are integrated and
coordinated at the cell membrane.
According to a recent model, intracellular components of the focal
adhesion complex and actin filaments associate with integrins upon
integrin engagement with the extracellular matrix. In the presence of
active Rho, these complexes and actin cluster by acto-myosin contraction, which leads to focal adhesion and stress fiber formation (13). Furthermore, this is thought to stimulate FAK
activation within the complexes in a manner similar to receptor
tyrosine kinase autophosphorylation and activation (8).
Supporting this model, among various Rho effector proteins such as
Rhotekin, Rhofilin, protein kinase N, Citron, p140mDia, PRK2,
phosphatidylinositol-4-phosphate 5-kinase [PI(4)P5-kinase], and
Rho-kinases (ROK
/Rho-kinase, ROK
/p160ROCK)
(31, 43, 48, 59, 60, 74-76), activation of Rho-kinase causes myosin light-chain phosphorylation, which may stimulate acto-myosin contraction (36). In addition, activation of
another Rho effector, PI(4)P5-kinase, leads to increased
phosphatidylinositol-4,5-bisphosphate [PI (4,5)P2]
levels, which facilitates the dissociation of profilin and gelsolin
from actin and allows net actin polymerization (35).
Nerve growth factor (NGF)-induced neurite outgrowth is controlled by
the Rho family of GTPases at the structural level. Previously, we have
shown that Rac activity is required for neurite elongation and tension
formation in the axon (2, 40). In contrast, Rho activity was
found to be inhibitory for neurite outgrowth since it caused growth
cone collapse as well as cell rounding in native PC12 cells (34,
71). Thus, it has been recently suggested that in contrast to
fibroblasts, where Cdc42, Rac, and Rho work in a linear fashion
(56), Rac and Rho have opposite actions on the cytoskeleton
in neuronal cells (38). In the present study, we present
evidence that the SH2/SH3 domain containing adapter protein v-Crk can
participate in LPA signaling to RhoA, leading to biogenesis of focal
adhesions and actin stress fibers in PC12 cells. These cytoskeletal
effects appear to be concomitant with the ability of v-Crk to bind
stably to focal adhesions and elevate the expression of specific focal
adhesion proteins. Hence, our results raise the possibility that
adapter proteins can act as scaffolds during the synthesis of focal
adhesions and shape changes in neuronal cells.
 |
MATERIALS AND METHODS |
Construction of expression vectors, transfection, and cell
lines.
PC12 cells expressing v-Crk (clones V15 and V1) and
R273N-v-Crk (an SH2 mutant of v-Crk) have been previously described
(28, 70). To generate stable PC12 cell lines expressing SH3
mutants of v-Crk, we subcloned BSP-v-Crk cDNA (pCT10) carrying the
D386DRHAD insertional mutation (51) into the pMEXneo
mammalian expression vector. Briefly, an AlwNI fragment
containing the entire coding region of mutant v-Crk was cloned into
EcoRI-BamHI-digested pMEXneo with
BamHI-EcoRI linkers, after which 20 µg of
plasmid DNA was purified and transfected into PC12 cells by the
Lipofectamine method. Stable cell lines of clonal origin were obtained
and expanded as described previously (28). All constructs
were sequenced prior to transfection to verify sequence integrity. To
verify that D386DHRAD-v-Crk behaved as a loss-of-SH3-function mutant, wild-type v-Crk SH3 or D386DHRAD mutant SH3 domains were PCR amplified from the purified pMEXneo plasmid DNA with the forward primer 5'CCGTGCGGATCCGTGCGAGCTCTCTTTGACTTT3' and the reverse primer
5'CTAATTGAATTCTCTCGACGTAAGGAACAGGTA3' engineered with
5' BamHI and 3' EcoRI restriction sites,
respectively. Following PCR amplification, clones were sequenced to
verify sequence integrity and ligated into
BamHI-EcoRI-linearized pGEX-2TK plasmid DNA
(Pharmacia). The glutathione S-transferase (GST),
GST-CrkSH3, or GST-D386DHRAD-Crk SH3 fusion proteins were expressed in
Escherichia coli DH5
cells after induction with 1 mM
isopropyl-
-D-thiogalactopyranoside (IPTG) for 3 h
at 37°C. The bacteria were lysed by sonication in bacterial lysis
buffer (1% Triton X-100, 20 mM Tris-Cl [pH 7.5], 150 mM NaCl, 1 mM
phenylmethylsulfonyl fluoride) and clarified by centrifugation at
8,500 × g for 20 min. GST fusion proteins were
purified from the lysate over GSH-Sepharose resin (Pharmacia), eluted
with 20 mM glutathione (GSH), dialyzed against phosphate-buffered saline (PBS), and stored at
70°C (17). pGEX-2TK contains
the recognition sequence for the catalytic subunit of cyclic
AMP-dependent protein kinase located between the GST domain and the
multiple-cloning site. GST fusion proteins were labeled with purified
bovine heart kinase (Sigma; P2645) and [
-32P]ATP
(3,000 mCi/mmol) as specified by the manufacturer of pGEX-2TK (Pharmacia; 27-4587-01), and all fusion proteins were labeled to
similar specific activities.
SH3 domain overlay assay.
To quantify binding of v-Crk or
D386DHRAD-v-Crk SH3 domains to proline-rich sequences, the high
affinity Crk-binding sequence (CB1) derived from amino acids 282 through 294 in C3G (SPPPALPPKKRQ) was cloned into pGEX-2T and expressed
as a GST fusion protein (37). As a control for binding
specificity, a mutated sequence containing K10L (SPPPALPPKLRQ) was used
in place of the wild-type sequence since it has been shown that lysine
is absolutely required for Crk binding to CB1 (37). GST or
GST fusion proteins (3.5 µg) containing CB1 or K10L-CB1 were
separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) (12% polyacrylamide) and transferred to Immobilon P
membranes. The membranes were incubated for 1 h at room
temperature in blocking buffer (150 mM NaCl, 20 mM Tris-Cl [pH 7.5],
1% [wt/vol] bovine serum albumin [BSA]), rinsed with Tris-buffered
saline, and incubated, with gentle shaking, at 4°C overnight with 5 µg of [32P]GST or [32P]GST-SH3 domains
per ml in SH3 overlay solution containing 1% BSA, 20 mM Tris-Cl (pH
7.4), 1 mM dithiothreitol, and 0.1% Tween 20. The filters were washed
three times, and bound radioactivity was detected by autoradiography.
Tissue culture and stimulation of cells.
PC12 cells and all
v-Crk subclones were maintained in Dulbecco's modified Eagle's medium
(DMEM; Gibco BRL) containing 10% horse serum and 5% calf serum
(Gemini Bioproducts, Inc.) and incubated in a humidified atmosphere at
37°C under 5% CO2. To isolate v-Crk-expressing flat
cells (V15F and V1F) from round (V15R and V1R) cells, the cells were
plated in 75-cm2 flasks with screw caps, and after 12 h round cells were lifted off the substratum by slight manual
trituration of the cells. Medium containing the floating round cells
was then transferred to another flask, and the flask containing the
flat cells was washed twice with medium to remove any remaining round
cells. To ADP-ribosylate and inhibit Rho, 100 µg of C3 toxin per ml
was added directly to the culture medium and the cells were treated for
12 h (34, 39) before any further treatment. For serum starvation assays, the cells were plated in serum-containing medium and
24 h later were switched to defined DMEM which contained 5 µg of
insulin per ml, 5 µg of transferrin per ml, 10
4 M
putrescine, 20 nM progesterone, 30 nM sodium selenite, and 1 U of
thrombin per ml (all chemicals from Sigma). The cells were kept in
defined DMEM overnight before any treatment. For morphological assays,
1 µM LPA (Sigma), 15% serum (Gibco BRL), or 100 ng of NGF
(Collaborative Biomedicals) per ml was added to the culture medium for
the indicated times. Since insulin can activate tyrosine kinase
receptors which may activate Rho family GTPases, we also tested DMEM
without insulin and obtained similar results. Phase-contrast photographs of cells were taken through a Zeiss Axiovert 100 microscope equipped with an Achrostigmat Ph1 objective (32×, 0.4 numerical aperture) and a camera with Kodak T-max 100 film. To measure the changes in cell surface areas, we photographed random areas of cells
under each treatment protocol. These photographs were then scanned with
a Nikon Scantouch and Adobe Photoshop software. The contours of
individual cells on each photograph were then marked, and their surface
area was measured with NIH image software. The raw data obtained by
this procedure was then processed for statistical analysis.
TLC and HPLC analysis of PIP2 levels.
Phospholipid labeling
and extractions were based on the thin-layer chromatography (TLC)
method (11). Briefly, equivalent numbers of cells were
maintained in 15% serum in phosphate-free DMEM and labeled for 16 h with 20 µCi of [32P]orthophosphate. The cells were
washed with PBS and lysed in acidic chloroform-methanol. The organic
phase was reextracted with 100 mM EDTA in acidic chloroform-methanol
and dried under N2. Lipids were separated by TLC with
commercial, nonradioactive PI(4)P and PI(4,5)P2 as markers
in a chloroform-methanol-4.3 M ammonium hydroxide (9:7:2) solvent
system. The TLC plates were analyzed with a phosphorimager
(PhosphoroImager SI; Molecular Dynamics Inc., B&L Systems, Zoetermeer,
The Netherlands). Spots were quantified with ImageQuaNT software,
version 4.2, Microsoft for Windows. For high-pressure liquid
chromatography (HPLC) analysis, extracted lipids were deacetylated with
methylamine and compared with [3H]PI(4)P,
[3H]PI(3,4)P2, and
[3H]PI(4,5)P2 standards.
Transient DNA transfections and kinase assays.
293T cells
were transfected with the Stratagene MBS mammalian transfection kit
(no. 200388), with minor modifications. Briefly, in 60-mm tissue
culture plates, cells were plated at approximately 50% confluency in
DMEM containing 10% fetal calf serum. After being washed in PBS, the
cells were transfected with up to 6 µg of plasmid DNA containing
either pMEX (control), pCMX-mycROCK, pMEX-v-crk,
pJ3H-PAK1, pEXV-V12rac1, pEXV-N19rhoA,
or pcEXV-rhoA in DMEM containing 6% modified bovine
solution. In some experiments, cells were transfected with 0.3 µg of
pEGFP (Clontech), a plasmid encoding the green fluorescent protein, so
that transfection efficiency could be monitored at 485 nM with a
fluorescein isothiocyanate emission filter. After 3 h in 6%
modified bovine solution, the medium was changed to DMEM-10% fetal
calf serum for an additional 30 h, after which the cells were
lysed in 500 µl of nonionic lysis buffer containing 1% HNTG (20 mM
HEPES, 150 mM NaCl, 1% Triton X-100, 10% glycerol). Samples were
normalized for protein and clarified by centrifugation at 13,000 × g for 5 min, and 1 µg of anti-Myc antibody (monoclonal
antibody [MAb] 9E10; Calbiochem no. OP10-Q) was added to lysates for
3 h, after which immune complexes were collected with rabbit
anti-mouse antibody-Sepharose (Jackson Laboratories) beads for 1 h. After being washed three times with 0.1% HNTG, the beads were
resuspended for 30 min with gentle agitation in 50 µl of kinase
buffer containing 5 µCi of [
-32P]ATP, 2 µM cold
ATP, 10 mM MnCl2, and 5 µg of histone H1 as the substrate. To stop the reaction, 4× electrophoresis sample buffer was
added and the mixture was boiled for 5 min. Samples were resolved by
SDS-PAGE (8.5% polyacrylamide) and transferred to Immobilon P
membranes (Millipore), and radioactivity was detected by
autoradiography of the membranes. The membranes were subsequently
immunoblotted with anti-Myc MAb to determine expression levels of
myc-p160ROCK fusion protein. To assay the activation status
of PAK65, JNK, and S6 kinase, native PC12 cells, v-Crk, R273N-v-Crk, or
D386DRHAD-v-Crk cells were lysed as above and immunoprecipitated with
either anti-PAK65 (provided by Gary Bokoch, Scripps Clinic, La Jolla,
Calif.), anti-S6 kinase (provided by M. Chou and J. Blenis, Harvard
University, Boston, Mass.), or commercial anti-JNK antibody (Santa Cruz
no. 15701A). In vitro kinase assays were performed as above with 5 µg
of myelin basic protein (MBP) for PAK65, S6 for S6 kinase, or GST
containing the first 79 amino acids of c-Jun (22) for JNK.
Preparation of lysates and immunoblotting.
To examine the
expression levels of cytoskeletal proteins, detergent lysates of cells
were prepared in RIPA buffer containing 50 mM NaCl, 10 mM Tris (pH
7.4), 1 mM EDTA, 1% Triton X-100, 1% sodium deoxycholate, and a
cocktail of protease inhibitors (Complete; Boehringer Mannheim) or
modified RIPA buffer containing 150 mM NaCl, 50 mM Tris (pH 7.4), 1%
Nonidet P-40, 0.5% sodium deoxycholate, and protease inhibitors.
Modified RIPA buffer was used for immunoblotting of integrins. After 15 min on ice, lysates were clarified by centrifugation in a
microcentrifuge, and protein concentrations were quantified by the
Bio-Rad protein assay. Equivalent amounts of protein-containing lysates
were boiled in sample buffer under reducing or nonreducing (for
5- and
v-integrins) conditions and
resolved by SDS-PAGE (6% polyacrylamide for FAK, vinculin, talin, and
paxillin and 7.5% polyacrylamide for
1-integrin,
-actinin, v-Crk, actin,
5-integrin,
p130cas,
3-integrin, and
v-integrin), and immunoblotting was carried out as
described previously (2). Briefly, the membranes were incubated for 4 h in 10 mM Tris (pH 7.4)-150 mM NaCl-10% Triton X-100 (wash solution) with 10% fetal calf serum to block nonspecific binding. They were then incubated in primary antibodies for 2 h at
the following dilutions; talin,
-actinin, and vinculin (MAbs from
Sigma) at 1:500; paxillin and FAK (MAbs from Transduction Labs) at
1:1,000; actin (MAb from Boehringer Mannheim) at 1:500; p130cas (MAb from Santa Cruz) at 1:1,000;
3-integrin (polyclonal Ab provided by L. Reichardt,
University of California, San Francisco) at 1:1,000;
5-integrin (polyclonal Ab provided by F. Giancotti, Memorial Sloan-Kettering Cancer Center) at 1:500;
v-integrin (polyclonal Ab from Chemicon International
Inc.) at 1:1,000; and
1cyto-integrin (polyclonal Ab
provided by L. Reichardt) at 1:1,000. MAbs (anti-3C2) to the Gag region
of v-Crk have been described previously (70). Following
incubation with primary antisera, immunoblots were reblocked for 30 min
and incubated in polyclonal horseradish peroxidase-conjugated
anti-mouse or anti-rabbit (Amersham) antibodies for 90 min. The blots
were processed and exposed to films by the enhanced chemiluminescence
method (Amersham). Under nonreducing conditions, no signal for
1-integrin was detected, suggesting that the antigenic
epitope was not recognized; also, the molecular weight of
3-integrin increased slightly as expected (reference
63 and data not shown).
To detect
1-integrin, biotin labeling of cell surface
proteins was performed (52). Briefly, cells were washed in
PBS followed by borate buffer (50 mM sodium borate, 150 mM NaCl [pH
8.0]) and incubated with 100 µg of
D-biotinoyl-
-aminocapronic
acid-N-hydroxysuccinimide ester (Boehringer Mannheim)/ml of
borate buffer for 30 min at room temperature. Labeled cells were then
collected from the plates in Tris buffer (50 mM Tris, 150 mM NaCl [pH
8.0]), centrifuged briefly, and washed twice in Tris buffer. The cells
were then lysed in modified RIPA buffer on ice, the lysates were
cleared, and protein was measured from the supernatants as described
above. Lysates containing 2 mg of total protein were incubated with
protein A-Sepharose beads (Pharmacia) passified with anti-mouse
immunoglobulin G (Cappel) for 2 h at 4°C and then centrifuged to
clarify the lysates. A 3-µl volume of 3A3 MAb
(anti-
1-integrin MAb provided by David Turner, State
University of New York, Syracuse, N.Y.) and anti-mouse immunoglobulin G
bound to protein A-Sepharose beads (30 µl packed volume) were then
added to each lysate. The bound proteins were immunoprecipitated and
resolved by SDS-PAGE (10% polyacrylamide), and biotinylated
1-integrins were detected with horseradish
peroxidase-conjugated streptavidin (Amersham).
Immunofluorescence labeling.
PC12 or v-Crk-expressing cells
were plated on poly-L-lysine-coated glass coverslips in
serum-containing medium. At 24 h after plating, the cells were
serum starved for 3 h to sensitize them for the serum response and
then serum was reintroduced to the medium for 3 h. The cells were
then washed in PBS and fixed in 3% paraformaldehyde in 0.9 mM
CaCl2- and 0.5 mM MgCl2-containing PBS for 20 min at room temperature. Cell membranes were permeabilized by
incubation of cells in 0.2% Triton X-100-1% blocking (horse or goat)
serum in PBS for 15 min. Glass coverslips were then placed upside down
on 150-µl droplets of various dilutions of primary antibodies in PBS
containing 0.2% Triton X-100 and 0.1% blocking serum pipetted on
Parafilm. After a 1-h incubation, coverslips were washed three times in
PBS, blocked in PBS containing 0.2% Triton X-100 and 5% blocking
serum, and placed for 1 h onto droplets of 1/100-diluted
fluorescein isothiocyanate-conjugated anti-mouse antibodies or
anti-rabbit antibodies (Vector Labs) and 0.5 µg of
tetramethylrhodamine-5-isothiocyanate-conjugated phalloidin (Sigma) in
PBS containing 0.2% Triton X-100 and 0.1% blocking serum. The cells
were then washed four times in PBS for 10 min and once in deionized
H2O for 5 min and mounted on glass slides with Gelvatol.
Staining was detected with a Zeiss Axiovert 100 microscope equipped
with a plan-Neofluar objective (100×, 1.3 numerical aperture), and
photographs were taken with Kodak Elite 400 film. In some experiments,
glass coverslips were coated with 5 µg of fibronectin (Boehringer
Mannheim) per cm2, 1 µg of laminin (Sigma) per
cm2, 8 µg of collagen type I (Sigma) per cm2,
10 µg of collagen type IV (GIBCO) per ml, and 33 µg of vitronectin (Calbiochem) per ml. Also, to overcome desensitization and test if the
adhesions would acquire a more mature phenotype with thicker actin
cables, we serum starved cells plated on vitronectin for 12 h
(hence downregulating Rho activity) and then treated them with 1 µM
LPA or serum (15%) for 3 h before performing immunofluorescence labeling. We did not detect any change in the form of adhesions generated under these conditions compared to those formed in cells maintained in serum.
Analysis of apoptosis.
Native PC12 cells or v-Crk-expressing
flat cells were cultured as above in 12-well plates, and triplicate
plates were seeded with each cell line. Triplicate plates were treated
in the presence or absence of serum, after which viability was analyzed
by the LIVE/DEAD Viability/Cytotoxicity kit (Molecular Probes no.
L-3224). This kit contains a two-color fluorescence assay that measures (i) intracellular esterase activity (a sign of viability) via the
enzymatic conversion of nonfluorescent cell-permeant calcein AM to the
intensely green polyanionic calcein, which is retained in live cells,
and (ii) plasma membrane integrity by means of ethidium homodimer,
which enters damaged membranes (a sign of cytotoxicity) and undergoes a
40× enhancement of red fluorescence upon binding DNA. The withdrawal
experiments were begun at least 24 h after plating and when cell
confluency approached 70%. After serum withdrawal, the cells were
gently washed with 5 µl of PBS containing 0.9 mM MgCl2
and 0.5 mM CaCl2, after which 800 µl of LIVE/DEAD assay
reagent (containing 4 µM ethidium homodimer and 2 µM calcein AM in
PBS) was added to each well. The cells were incubated for 30 min at
37°C, and the percentages of live and dead cells were obtained by
counting more than 1,000 cells per well from several random fields with
a conventional 485-nm fluorescein excitation filter.
 |
RESULTS |
v-Crk induction of lamellipodia and somal flattening in PC12 cells
is RhoA dependent and requires SH2 and SH3 domains of v-Crk.
LPA,
a major component of serum, induces the generation of focal adhesions
and stress fibers in quiescent fibroblasts by a mechanism that appears
to be dependent on the activation of the low-molecular-weight GTPase
RhoA (62). In neuronal cells, including rat pheochromocytoma
(PC12) cells, LPA causes growth cone collapse and neurite retraction
(33, 66, 72), while inhibition of RhoA by C3 toxin leads to
neurite outgrowth (34, 55). Previously, we reported that
PC12 cells expressing the v-Crk adapter protein display an accelerated
velocity of neurite outgrowth when treated with NGF in low (3%) serum
(22, 28). However, when these cells were maintained in high
(15%) serum, most of the cells developed lamellipodia with ruffling
along the edges and exhibited marked somal flattening (Fig.
1 and 2A,
arrows). To examine these cells in more detail, we isolated an
essentially pure population of v-Crk-expressing flat cells (surface
area, 617 ± 42 µm2 [mean ± standard error])
from original v-Crk-expressing clones (V15 and V1) by physically
separating them from round cells (surface area, 107 ± 73 µm2) by manual trituration (Fig. 1, compare panels B and
C). These flat cells will be referred to as V15F (v-Crk clone 15 flattened) throughout the paper. Similar results were observed with
v-Crk clone V1, although unless otherwise indicated, only results from V15F cells are shown. Lamellipodium formation and somal flattening were
dependent on the presence of serum (15%), since V15F cells readily
reverted to the round phenotype when serum was withdrawn (Fig. 1A and
Fig. 2B). The mean surface area of flat cells after serum withdrawal
(137 ± 7 µm2) was significantly different from the
value obtained in serum (t test, P < 0.001). Flattening could also be induced upon treatment of cells with 1 µM LPA for 3 h in the absence of serum (Fig. 2D), which results
in activation of Rho in PC12 cells (71). Treatment of V15F
cells with 100 µg of C3 toxin per ml to block Rho activation, in
contrast, prevented flattening in serum-containing medium (Fig. 2C) or
by LPA (data not shown), suggesting that this effect is mediated by
Rho. Moreover, as shown in Fig. 2C, C3 toxin treatment resulted in the
formation of short neurite-like processes, although such neurite
outgrowth was considerably less pronounced than in cells treated with
NGF (not shown).

View larger version (126K):
[in this window]
[in a new window]
|
FIG. 1.
Quantitative changes in the surface area of
v-Crk-expressing cells in the presence and absence of serum and upon
treatment with LPA or NGF. (B) When maintained in 15% serum-containing
medium, the majority of v-Crk-expressing cells became flattened. (C)
These cells were separated from the minor subset of cells that remained
round in serum-containing medium, as described in the text. (A) When
serum was withdrawn, the flattened v-Crk cells reverted to the round
phenotype. (D) Bar graphs show the changes in mean surface areas of
cells under various treatment conditions. The standard errors are also
shown. The surface areas were measured by scanning photographs of
random fields of cells and measuring the scanned images of individual
cells on each photograph as described in Materials and Methods. (Bar 1)
v-Crk cells that remained round in 15% serum; surface area, 107 + 73 µm2 (n = 51). (Bar 2) Flat v-Crk cells
in medium without serum; mean surface area, 137 + 7 µm2 (n = 40). (Bar 3) Flat v-Crk cells
that were maintained in the absence of serum and later treated with 1 µm LPA; mean surface area, 411 + 50 µm2
(n = 46). (Bar 4) Flat v-Crk cells in 15%
serum-containing medium; mean surface area, 617 + 42 µm2 (n = 45). (Bar 5) Flat v-Crk cells
maintained in 15% serum and then treated with 100 ng of NGF per ml for
5 days; mean surface area, 1,276 + 175 µm2
(n = 52). The differences between mean surface areas of
round versus flat v-Crk cells in 15% serum (t test,
P < 0.001), flat v-Crk cells in the absence versus the
presence of 15% serum (t test, P < 0.001),
flat v-Crk cells in the absence of serum versus after LPA treatment
(t test, P < 0.001), and v-Crk cells kept
in serum versus after additional NGF treatment (t test,
P < 0.001) were significant.
|
|

View larger version (155K):
[in this window]
[in a new window]
|
FIG. 2.
v-Crk causes serum-induced cell flattening and
lamellipodium formation in PC12 cells through the activation of Rho.
v-Crk-expressing PC12 cells were grown in the presence (A and C) or
absence (B and D) of 15% serum-containing medium. (A) Representative
shape changes of PC12 cells expressing v-Crk when cultured in 15%
serum. Cells flatten out and grow lamellipodia along their edges
(arrows). (B) When cells are serum starved for 12 h, no flat cells
are observed. (C) Cells maintained in 15% serum were treated with 100 µg of C3 exoenzyme per ml for 12 h. (D) Cells were maintained in
serum-free medium for 12 h and then treated with 1 µM LPA for
3 h. Magnification, ×26.5. Bar, 50 µm.
|
|
Previously, we have shown that v-Crk binds stably to the
tyrosine-phosphorylated focal adhesion proteins paxillin and
p130cas through its SH2 domain and to guanine
nucleotide exchange factors (GNEFs) SOS1 and C3G through its SH3 domain
(6) and, in doing so, may couple tyrosine kinase cascades to
small GTPases in the neuronal cytoskeleton. To investigate whether
lamellipodium formation was dependent upon SH2- or SH3-mediated
pathways, we examined LPA-induced cell flattening in PC12 cells
overexpressing SH2 or SH3 domain mutants of v-Crk. However, to first
verify that these mutants were functionally inactive, we examined the
binding of the SH2 mutants to tyrosine-phosphorylated paxillin and the
binding of the SH3 mutants to a proline-rich peptide derived from C3G, since these proteins represent high-affinity Crk SH2- and SH3-binding proteins, respectively (6, 37) (Fig.
3). To determine whether R273N-v-Crk
(SH2 mutant) perturbed the binding to tyrosine-phosphorylated paxillin,
detergent lysates of v-Crk-expressing PC12 cells, R273N-v-Crk, and the
linker insertion D386DRHAD-v-Crk were immunoprecipitated with anti-Gag
antibodies and subjected to Western blotting with antipaxillin (Fig.
3A). In contrast to wild-type v-Crk and D386DRHAD-v-Crk, the
R273N-v-Crk mutant was completely defective in its ability to
coprecipitate paxillin, indicating a general defect in binding to a
tyrosine-phosphorylated substrate.

View larger version (54K):
[in this window]
[in a new window]
|
FIG. 3.
Serum- and LPA-induced cell flattening is blocked by
mutation in the v-Crk SH2 or SH3 domain. (A) R273N-v-Crk (SH2 mutant)
is defective in binding tyrosine-phosphorylated paxillin.
D386DRHAD-v-Crk, R273N-v-Crk, or wild-type (WT) v-Crk-expressing
cells were kept in the presence or absence of NGF, and the resulting
detergent lysates were immunoprecipitated with anti-Gag antibodies and
subjected to Western blotting with antipaxillin MAb (arrow). (B) Linker
insertion mutations in the Crk SH3 domain disrupt binding to
proline-rich peptides derived from the Crk-binding region of C3G. GST
or GST fusion proteins containing either wild-type v-Crk SH3 or
D386DRHAD SH3 domains were labeled with
[32P]orthophosphate (see Materials and Methods). To
quantify the binding of the 32P-labeled GST proteins to
C3G-derived peptides, 3.5 µg of GST (lanes 1), GST-C3GCB1
(SPPPALPPKKRG) (lanes 2), or GST-C3GK10L
(SPPPALPPKLRG) (lanes 3) was electrophoretically resolved in
a 13% acrylamide gel and transferred to Immobilon P, and membrane
strips were incubated with [32P]GST,
[32P]GST-v-Crk SH3, or
[32P]GST-D386DRHAD-v-Crk SH3 overnight at 4°C. After
being washed, the filters were exposed to X-ray film (autoradiogram) or
excised and counted in a -counter (histograms). (C) Morphological
responses of cells expressing v-Crk mutants towards LPA. Native PC12
cells (panels i and iv), R273N-v-Crk cells (panels ii and v), or
D386DRHAD-v-Crk cells (panels iii and vi) were grown in serum-free
medium for 12 h (panels i to iii) and then treated with 1 µM LPA
for 3 h (panels iv to vi). Similar results were obtained with
serum (not shown). BSP v-CrkSH3 is th esame as D386DRHAD-v-CrkSH3. The
structures and positions of SH2 and SH3 mutations are indicated.
Magnification, ×32.
|
|
To determine if the linker insertion mutation in the v-Crk SH3 domain
impaired its binding to proline-rich sequences, we generated a
GST-wild-type v-Crk SH3 domain and a GST-D386DRHAD-v-Crk SH3 domain
after cloning into pGEX2TK, a vector which, in addition to producing a
GST fusion, contains a cyclic AMP-dependent protein kinase
phosphorylation site between the GST and the SH3 domain, enabling
fusion proteins to be labeled to high specific activity (see Materials
and Methods). To quantify the binding of GST-SH3 fusion proteins to
proline-rich sequences, GST, GST-C3G CB1 (SPPPALPPKKRG), and
GST-C3G K10L (SPPPALPPKLRG) were
electrophoretically resolved, transferred to Immobilon, and incubated
with either [32P]GST, [32P]GST-wild-type
v-Crk SH3, or [32P]D386DRHAD-v-Crk in an SH3 overlay
assay. As shown in Fig. 3B, the insertional mutation within the Crk SH3
domain decreased its binding to the C3G peptide by more than 99%,
indicating a total-loss-of-function mutation by this criterion. Given
the fact that v-Crk SH2 and SH3 mutants were completely defective in
binding their physiologically relevant proteins, we next compared the
response of PC12 cells expressing these mutants to LPA (Fig. 3C). In
contrast to results obtained with wild-type v-Crk PC12 cells (Fig. 2D),
no cell flattening was induced in either mutant cell by treatment with
LPA. Also, no cell flattening occurred when the cells were maintained
in 15% serum (data not shown), suggesting that both the SH2 and SH3 domains of v-Crk are essential for the LPA- and serum-induced cell
flattening. Moreover, consistent with previous results (33), LPA treatment of native PC12 cells resulted in complete rounding (Fig.
3C, panels i and iv).
v-Crk-expressing PC12 cells display isotropic growth with broadened
lamellipodia after NGF treatment unless Rho activity is downregulated
by serum withdrawal.
To investigate the relationship between
neurite elongation and lamellipodium formation, V15F cells were
maintained in 15% serum and treated continuously with 100 ng of NGF
per ml for 5 days (Fig. 4). In contrast
to native PC12 cells, which grew long, branching neurites with
well-developed growth cones in the presence of NGF (Fig. 4A), V15F
cells grew broadened lamellipodia after NGF treatment (Fig. 4E and F,
arrowheads). This NGF-induced isotropic growth of V15F cells was
evident as a twofold increase in the mean surface area of the cells
(Fig. 1D, compare histograms 4 and 5). Consistent with results in Fig.
3, neither D386DRHAD-v-Crk nor R273N-v-Crk cells exhibited somal
flattening in NGF and 15% serum, although their responses to NGF were
quite different (Fig. 4B and C). Thus, while R273N-v-Crk cells were
defective in neurite elongation, SH3 mutants appeared to be equivalent
to wild-type PC12 cells in their morphological appearance and velocity
of differentiation. In contrast, when V15F cells were serum starved for
12 h before and during NGF treatment, their somas rounded and the
cells extended long neurites (Fig. 4D). Consistent with previous
results, the growth rate of these neurites was initially much higher
than that of neurites extended from wild-type PC12 cells (reference
70 and data not shown). These data suggest that
NGF-induced neuritogenic signals cannot be processed properly in
flat-phenotype V15 cells unless Rho signaling is downregulated by serum
withdrawal.

View larger version (104K):
[in this window]
[in a new window]
|
FIG. 4.
LPA and serum antagonize the neurite-promoting effects
of v-Crk unless serum is withdrawn. PC12 cells (A), D386DRHAD-v-Crk
cells (B), R273N-v-Crk cells (C), or v-Crk cells (E and F) were
cultured for 5 days in 15% serum containing NGF (100 ng/ml). v-Crk
PC12 cells exhibiting broadened lamellipodia and flattening in panels E
and F are indicated by solid arrows. In panel D, serum was removed from
v-Crk-expressing cells for 12 h and the cells were cultured in
serum-free medium containing 100 ng of NGF per ml. Note the absence of
somal flattening in these cells (compare panel D with panels E and
F).
|
|
The Rho effector kinases, PI(4)P5-kinase and p160ROCK,
but not the Rac/Cdc42 effector kinases, PAK and S6 kinase, are
activated by v-Crk.
Among proteins that bind Rho, PI(4)P5-kinase
(11) and p160ROCK (Rho-associated
coiled-coil-containing protein kinase) are activated by the GTP-bound
form of Rho (31, 42, 50). To assess whether v-Crk modulates
the activities of these Rho effectors, we measured the production of
PIP2 in v-Crk-expressing cells as a product of
PI(4)P5-kinase (Fig. 5). Analysis of the
total PIP2 level revealed that it was increased about
1.6-fold in V15F cells maintained in 15% serum compared to levels
found in wild-type cells. HPLC analysis of extracted lipids from V15F
cells with respect to known standards of [3H]PI(4)P,
[3H]PI(4,5)P2, and
[3H]PI(3,4)P2 revealed that v-Crk selectively
elevated PI(4,5)P2 levels whereas PI(3,4)P2 was
undetectable under these conditions (data not shown). These data
support a role for v-Crk in Rho activation since GTP-bound recombinant
Rho has been shown to bind PIP5-kinase, resulting in the selective
production of PI(4,5)P2 (11). Interestingly, in
R273N-v-Crk- and D386DRHAD-v-Crk-expressing cells, the levels of
PI(4,5)P2 were approximately 47 and 67% of control values, respectively. These results suggest that basal levels of
PI(4,5)P2 are increased in the presence of wild type v-Crk
and that the SH2 and SH3 mutants of v-Crk partially inhibit its
production.

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 5.
PI(4,5)P2 production in PC12 cells
expressing v-Crk and v-Crk mutants. Native PC12 cells, v-Crk cells
(clones V15F and V1F), R273N-v-Crk cells, or D386DRHAD-v-Crk cells
were maintained in 15% serum, after which they were briefly starved
and incubated overnight with 20 µCi of
[32P]orthophosphate. Extracts were prepared from adherent
cells and normalized for cellular protein, and the resulting
radiolabeled lipids were subjected to TLC. 32P-labeled
PIP2 was deacylated and quantified with a PhosphorImager.
Values were normalized to the value in native PC12 cells (designated
100%) and are expressed as the mean and standard error
(P < 0.05 between V15F and V1F and native cells,
indicated by asterisk) of four independent experiments. HPLC analysis
on extracted lipids demonstrated that only PI(4,5)P2, and
not PI(3,4)P2, was produced in these cells.
|
|
To directly test the effect of v-Crk on p160ROCK
activation, we used a transient-transfection assay whereby an
expression vector encoding myc-tagged ROCK
(pCMX-mycROCK) was cotransfected with an expression vector
for v-crk (pMEXneo-v-crk) into 293T cells. As a
positive control for p160ROCK activation, cells were
cotransfected with pCMX-mycROCK and
pcEXV-V14rhoA, which encodes the constitutively active form
of RhoA. After 24 h of incubation, the cells were lysed and
immunoprecipitated with anti-Myc MAbs to quantify p160ROCK
activity in a kinase assay with histone H1 as the substrate. Figure
6A and B show two independent experiments
demonstrating that when v-Crk was expressed, p160ROCK
activity was increased to levels similar to those seen after cotransfection of pcEXV-V14rhoA, suggesting that v-Crk lies
upstream of Rho with respect to p160ROCK activation. This
level of p160ROCK activation was quantitatively similar to
the magnitude of activation reported previously after transient
transfection of V14RhoA with p160ROCK in COS cells
(31). Moreover, as a control to show that v-Crk activation
of p160ROCK was Rho dependent, cells transfected with v-Crk
and mycROCK were cotransfected with either pEXV-N19RhoA or
pEXV-N17Rac-1, which encode dominant negative forms of Rho and Rac,
respectively (Fig. 6C). While v-Crk-mediated activation of
p160ROCK was strongly suppressed after transfection with
N19RhoA, there was little or no inhibition of p160ROCK
activation by v-Crk in the presence of N17Rac-1.

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 6.
v-Crk activates p160ROCK by transient
transfection into 293T cells. (A) 293T cells were transiently
cotransfected by the calcium phosphate method with 2 µg of
pCMX-myc-tagged ROCK (lanes 2 to 4) and either 2 µg of pMEXneo
(control, lane 2), pMEXneo-v-crk (lane 3), or activated
pcEXV-V14rhoA (lane 4) for 3 h. After an additional
36 h in 15% serum, the cells were washed and immunoprecipitated
with anti-Myc MAb. In the top panel, the level of p160ROCK
activity was determined in an in vitro kinase assay with 5 µg of
histone H1 as a substrate. The expression levels of
myc-p160ROCK and v-Crk, determined by Western blotting, are
shown in the respective bottom panels. (B) A replicate experiment,
except that cells were also transfected with 2 µg of
pMEXneo-R273N-v-crk plasmid DNA. (C) Effects of dominant
negative Rho or Rac on the v-Crk-induced activation of MycROCK.
Transfections were performed as above, except that 2 µg of
pEXV-N19rhoA (lane 2) or pEXV-N17rac1 (lane 3) was used as the control
for Rho specificity.
|
|
In contrast to Rho, GTP-bound Rac and Cdc42 bind to and activate the
serine/threonine kinases PAK (49) and S6 kinase
(12). To determine whether v-Crk plays a role in activation
of Rac/Cdc42-dependent protein kinases, PC12 cells and various
v-Crk-expressing PC12 cells were maintained in low serum for 12 h
and then stimulated with 15% serum or 15% serum plus 50 ng of NGF per
ml for 30 min. As shown in Fig. 7, the
kinase activities of cellular PAK65 (Fig. 7A) and S6 kinase (Fig. 7B)
were not significantly increased upon serum or NGF addition, nor did
v-Crk appear to hyperactivate their activities compared to control
cells. Further, to demonstrate that v-Crk did not stimulate
Rac/Cdc42-dependent kinases under conditions similar to those under
which it activated p160ROCK, 293T cells were also
transiently cotransfected with vector DNA or pMEX-v-crk and
an expression vector encoding hemagglutinin (HA)-tagged PAK
(pJ3H-PAK1) (Fig. 7C). In contrast to PAK activation by
V12Rac1 (a positive control for this experiment) and consistent with
the results obtained with cellular PAK, there was no observable activation of transfected PAK by v-Crk. In contrast to PAK and S6
kinase, serum stimulation of normal PC12 cells did result in the
activation of cellular JNK, and this appeared to be enhanced in V15F
cells (Fig. 7D). Interestingly, the serum-induced JNK activation was
almost completely abolished in PC12 cells expressing the SH3 mutant of
v-Crk (D386DRHAD-v-Crk), suggesting that it may have a dominant
negative effect in the JNK pathway. It is noteworthy that
D386DHRAD-v-Crk did not decrease PAK or S6 kinase activities relative
to the control levels, and this further suggests that the v-Crk- or
serum-induced activation of JNK may not result from a
Rac/Cdc42-dependent pathway in PC12 cells.

View larger version (48K):
[in this window]
[in a new window]
|
FIG. 7.
The Rac/Cdc42-activated protein kinases PAK and S6
kinase are not hyperactivated by v-Crk. (A and B) Native,
R273N-v-Crk-expressing, D386DHRAD-v-Crk-expressing, or
v-Crk-expressing PC12 cells were serum starved for 12 h (lanes 1)
and then stimulated with 15% serum (lanes 2) or 15% serum plus 50 ng
of NGF per ml (lanes 3) for an additional 30 min. The cells were
washed, detergent lysates were prepared, and 500 µg of total cellular
protein was immunoprecipitated with either anti-PAK65 polyclonal
antibody (A) or anti-S6 kinase polyclonal antibody (B). The kinase
activity was determined after incorporation of 32P into
myelin basic protein (MBP) or S6 proteins, respectively (indicated by
arrows). (C) 293T cells were transiently transfected as described in
the legend to Fig. 6A, except that 2 µg of pJ3H-PAK DNA and 2 µg of
either pEXV-V12rac1 (lane 2), pMex-v-Crk (lane 3), or pMEXneo control
(lane 4) were used. The cells were lysed and immunoprecipitated with
anti-HA antibodies, and kinase activity was measured with 5 µg of
myelin basic protein as the substrate (arrow). The expression of HA-PAK
by using anti-HA antibody is indicated in the bottom panel (arrow). (D)
Activation of cellular JNK by v-Crk and mutant v-Crk. PC12 cells and
wild-type or mutant v-Crk PC12 cells were treated as above and
immunoprecipitated with anti-JNK antibodies. Kinase activity was
measured after incorporation of 32P into the GST-c-Jun
1-79 substrate (arrow).
|
|
v-Crk induces stress fibers and focal adhesions at the cell
periphery in response to serum in PC12 cells.
In nonneuronal
cells, microinjection of an activated form of Rho or overactivation of
p160ROCK promotes actin stress fiber and focal adhesion
formation (42, 62). Neuronal cells, including PC12 cells,
rarely contain focal adhesions. Moreover, activation of Rho results in
retraction of neurites and cell rounding in NGF-treated PC12 cells
(33). Since the phenotypic response of v-Crk cells to LPA or
serum was reversed compared to that of wild-type cells, we investigated
the presence of focal adhesions in these cells by immunofluorescence
staining with antibodies against focal adhesion proteins. Neither PC12 cells nor V15F cells attached well to substratum in serum-deficient medium, since probably both serum-related factors and extracellular matrix are required for adhesion complexes to form (29).
Thus, PC12 and V15F cells were plated on
poly-L-lysine-coated glass coverslips in the presence of
serum which contains fibronectin and vitronectin, as well as
serum-related factors such as LPA. After overnight incubation, the
cells were stained with antibodies against the focal adhesion proteins
paxillin and vinculin as well as a battery of anti-integrin-specific
antibodies (Fig. 8 and data not shown).
In all experiments, the cells were counterstained with
rhodamine-conjugated phalloidin to detect F-actin. Interestingly, in
V15F cells, vinculin and paxillin were localized in dash-like adhesion
complexes (Fig. 8C and E) that were clearly associated with actin
cables which either crossed the whole cytoplasm or formed circular
cables around the cell periphery (compare Fig. 8C and D, and compare
Fig. 8E and F). In fact, when these immunofluorescent scans were merged
to identify points of colocalization, focal adhesions appeared yellow,
indicating extensive colocalization of vinculin and paxillin with actin
microfilaments (Fig. 8G and H). In contrast to V15F cells, vinculin or
paxillin staining showed no discernible dash-like complex formation in
native PC12 cells and actin staining was diffuse within the cytoplasm
of these cells (Fig. 8A and B). An important distinction, however,
between focal adhesion staining observed in fibroblasts and the
adhesions in V15F cells was that the latter were preferentially
localized to the cell periphery and the actin cables that associated
with them were considerably thinner. These adhesion complexes are
similar to the transitory-type focal adhesions or "immature" focal
adhesions described by Bershadsky et al. (5). Staining with
antibodies against Gag (to detect v-Crk) also revealed that Crk
localized to similar complexes (data not shown), consistent with
previous results obtained with fibroblasts (54).

View larger version (91K):
[in this window]
[in a new window]
|
FIG. 8.
v-Crk promotes the formation of stress fibers and focal
adhesions that contain vinculin and paxillin. Native PC12 cells (A and
B) or V15F cells (C to H) were cultured in 15% serum on
poly(L-lysine)-coated glass coverslips. The cells were
immunostained with antipaxillin (A and C) or antivinculin (E)
antibodies and counterstained with rhodamine-conjugated phalloidin (B,
D, and F) to detect actin microfilaments. Solid arrows demarcate areas
of well-defined peripheral focal adhesions that end in stress fibers
(compare the arrows in panels C and D and those in panels E and F).
Panels G and H show merged composites of vinculin and actin (G) and
paxillin and actin (H). Focal adhesions that stained yellow (arrows)
indicate regions of colocalization. Magnification, ×91. Scale bar, 3.3 µm in panels A and B; 10 µm in panels C through H.
|
|
To investigate whether v-Crk expression resulted in a redistribution of
integrins into focal adhesions, we surveyed a variety of
anti-integrin antibodies, including anti-
1,
anti-
3, anti-
v, and
anti-
1, in the V15F cells. In contrast to the
well-demarcated vinculin and paxillin staining observed in focal
adhesions,
1,
3, or
v
staining was predominantly punctate and did not localize to focal
adhesions (not shown). In fact, staining of
1-integrin, which represents a major integrin in PC12 cells (15), was
observed in punctate complexes at the periphery of lamellipodia. We did not detect any actin fibers associating with these punctate adhesions, suggesting that
1-integrin may not be the primary
integrin utilized by v-Crk. These results raise the possibility that
v-Crk regulates novel integrin pathways during focal adhesion
biogenesis. Since it has been reported that the type of matrix
determines the distribution of distinct integrins into focal contacts
(16), we also examined whether changing the extracellular
matrix type to vitronectin, fibronectin, collagen types I and IV, or
laminin would affect the pattern of staining of adhesion complex
proteins and actin in V15F cells. However, no noticeable change in the
staining of actin, integrins, or vinculin was detected on any of these
matrices (data not shown).
v-Crk-expressing cells contain an increased level of FAK, which is
constitutively active in adherent cells.
During focal adhesion
assembly, LPA or Rho activation causes tyrosine phosphorylation of
several cytoskeletal proteins, including paxillin,
p130cas, and FAK (39, 65). To test
whether v-Crk expression resulted in a modulation of FAK tyrosine
phosphorylation, we immunoprecipitated FAK from lysates of native PC12
cells and V15F cells and tested for tyrosine phosphorylation by
immunoblotting with an antiphosphotyrosine antibody. In contrast to
native PC12 cells, in which no tyrosine phosphorylation of FAK could be
detected, FAK was constitutively tyrosine phosphorylated in V15F cells
(Fig. 9A, top panel). Moreover, when the
immunoblots in Fig. 9A were stripped and reanalyzed for the levels of
FAK by anti-FAK immunoblotting, the expression of FAK was found to be
increased in V15F cells (Fig. 9A, bottom panel). To investigate whether
FAK phosphorylation was dependent on cell adhesion, V15F cells were
trypsinized and either replated on matrix for 4 h (Fig. 9B, lanes
2 and 3) or grown in suspension in the presence of serum for 4 h
(Fig. 9B, lane 4). Tyrosine phosphorylation of FAK was strictly
dependent on adhesion to matrix (Fig. 9B, compare lanes 2 and 4),
although the level of FAK expression remained elevated (compare lanes 3 and 4 in the bottom panel). Similarly, when V15F cells were treated
with C3 toxin for 12 or 24 h to cause cell rounding (Fig. 2C), FAK
tyrosine phosphorylation was also abolished while the expression of FAK
remained elevated (Fig. 9B, lanes 5 to 7). Since v-Crk expression
caused an upregulation in the level of FAK, we postulated that a change
in the level of adhesion proteins might explain the reversion of
phenotypic response of v-Crk-expressing PC12 cells to LPA and serum.
Therefore, we compared the expression of several cytoskeletal proteins
and integrins in the phenotypically "flattened" v-Crk-expressing
cells (V15F) to that in v-Crk-expressing cells that were phenotypically round (see Materials and Methods), as well as in mutant
v-Crk-expressing cells and naive PC12 cells (Fig.
10). Indeed, the amount of FAK was
increased in both round and flat v-Crk cells (Fig. 10, compare lanes 4 through 7 to lane 1). Also, the comparative levels in v-Crk cells
correlated with their phenotype in serum, such that flattening was seen
only in cells that contained higher levels of FAK. In contrast, total
Western blotting of native PC12 and SH2 and SH3 mutants did not show
detectable levels of FAK expression (lanes 1 through 3). This suggests
that expression of v-Crk in PC12 cells leads to upregulation of FAK in
these cells and also that there is a threshold level of FAK within
cells, below which the cells respond to serum by rounding up. In
addition to FAK, V15F cells exhibited an increase in the expression
level of paxillin,
3-integrin, and a
higher-molecular-weight form of
1-integrin (Fig. 10) but
not of other adhesion-related proteins such as vinculin, talin, and
p130cas. We did not detect any
5-integrin in PC12 cells (data not shown), and
1-integrin expression was unchanged in v-Crk PC12 cells
(Fig. 10). These data suggest that v-Crk expression leads to increased levels of specific adhesion proteins in PC12 cells.

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 9.
v-Crk elevates the expression and tyrosine
phosphorylation of FAK. (A) PC12 or V15F cells were maintained in low
serum (3%) for 4 h and then stimulated with either 15% serum or
15% serum plus 100 ng of NGF per ml for 5 or 30 min. Lysates were
normalized for cellular protein, immunoprecipitated with anti-FAK MAb,
and subjected to Western blotting with anti-PY (top panel). In the
bottom panel, the same blot was stripped and reprobed with anti-FAK
antibody. The constitutive level of tyrosine phosphorylation in the
presence of low serum probably reflects the fact that the cells were
kept in low serum for only 4 h, at which time they were still
predominantly flattened. (B) Tyrosine phosphorylation of FAK in V15F
cells is dependent on cell adhesion and Rho activation (lanes 2 to 7).
The cells were treated as in panel A, except in lane 4, where V15F
cells were treated with EDTA and grown in suspension in spinner flasks
with 15% serum for 4 h. In lanes 5 to 7, V15F cells were treated
in the absence (lane 5) or presence (lanes 6 and 7) of C3 toxin for 12 or 24 h. The levels and tyrosine phosphorylation of FAK are
indicated.
|
|

View larger version (86K):
[in this window]
[in a new window]
|
FIG. 10.
The expression levels of FAK, paxillin,
3-integrin, and a higher-molecular-weight form of
1-integrin are selectively increased in v-Crk-expressing
cells. D386DRHAD-v-Crk (lane 1), native PC12 cells (lane 2),
R273N-v-Crk (lanes 3), and round or flat forms of two independent
lines of v-Crk cells, V1 flat cells (lanes 4), V1 round cells (lanes
5), V15 flat cells (lanes 6), and V15 round cells (lanes 7), were
maintained in 15% serum. Round cells were obtained by slight manual
trituration of the cells, which lifted off the plate easily, leaving
the flattened cells which contained focal adhesions still attached.
After cell lysis, protein concentrations were normalized and 100 µg
of total cellular protein was analyzed by SDS-PAGE and Western blotting
with specific antibodies to Gag (v-Crk), vinculin, talin,
p130cas, 1-integrin, paxillin,
FAK, 3-integrin, and v-integrin, as
indicated. Expression of FAK was increased in both forms of v-Crk
cells, although to a lesser degree in the round cells (compare lanes 4 and 6, and compare lanes 5 and 7). 1-Integrin was
detected after cell surface biotinylation followed by
immunoprecipitation and immunoblotting with horseradish
peroxidase-conjugated streptavidin. Although another strain of PC12
cells expressed 1-integrin at high levels (lane 8), the
PC12 cells used in this study as well as v-Crk and mutant
v-Crk-expressing cells showed very low detectable levels of
1-integrin.
|
|
Expression of v-Crk confers resistance to apoptosis.
Cells
require anchorage to the substratum and the presence of growth factors
for survival. However, overactivation in the signaling cascades
initiated by either one of these factors can confer anchorage- or
serum-independent growth. Recently, it has been reported that
constitutively activated forms of FAK, which form, for example, by
targeting FAK to plasma membranes, protect cells from a specific form
of apoptosis called anoikis (19). To address whether the
expression of v-Crk confers resistance to apoptosis in PC12 cells, we
induced cell death by serum and growth factor withdrawal in V15F and
PC12 cells (Fig. 11). By 36 h
after serum withdrawal, about 50% of wild-type PC12 cells underwent apoptosis whereas more than 95% of the V15F cells remained alive. Similar results were obtained with other wild-type v-Crk-expressing clones (data not shown). Our results suggest that v-Crk can regulate survival signals and that ectopic expression of v-Crk renders PC12
cells resistant to apoptosis, probably via the upregulation and
activation of FAK.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 11.
v-Crk confers resistance to apoptosis during serum
withdrawal. Native PC12 or V15F PC12 cells were cultured in 15% serum
and transferred to serum-free medium for up to 36 h. Live versus
dead cells were scored by a two-color fluorescence assay involving
ethidium homodimer and calcein AM. Data show the mean and standard
error for three independent experiments.
|
|
 |
DISCUSSION |
The Rho family of GTP-binding proteins regulates rearrangement of
the actin cytoskeleton in many different cell types. In neuronal cells,
including PC12 cells, the interplay between neurite extension and
neurite retraction may be controlled in part by the relative activation
of Rac/Cdc42 and Rho (45, 47). Activated Rac and Cdc42 are
involved in maintaining growth cone structures such as lamellae and
filopodia, thereby facilitating neurite elongation, while activation of
Rho, for example by serum or LPA, induces cell rounding and inhibits
neurite outgrowth by causing growth cone collapse (38).
Evidence for this is supported by results obtained with
Drosophila embryos, in which dominant negative Rac impairs
axonal pathfinding in developing sensory neurons (44, 46).
In this paper, we present evidence that the SH2/SH3 domain-containing protein v-Crk activates downstream effectors of Rho but not Rac or
Cdc42 and reverses the cytoskeletal response of PC12 cells to LPA and
serum by causing cell flattening. PC12 flattening as a result of v-Crk
expression correlates with the formation of well-organized focal
adhesions and stress fibers, reflecting increased PI(4,5)P2
production and FAK activity and increased expression of FAK, paxillin,
3-integrin, and a higher-molecular-weight form of
1-integrin in the cells. It is possible that in
v-Crk-expressing PC12 cells higher levels of FAK and adhesion proteins
permit cell flattening and focal adhesion formation in response to Rho
activation, similar to that which occurs in fibroblasts, while in
native PC12 cells Rho activation causes cell rounding, presumably due
to below-threshold levels of FAK and adhesion-related proteins. Our
results suggest that the composition of cytoskeleton-associated
molecules in neuronal cells, as well as the relative activity of
adhesion complex-related signaling molecules, determines the response
of neurons to serum and growth factors. Moreover, our data support a
role for v-Crk as an intrinsic determinant for the organization of
adhesion complexes in PC12 cells.
The effects of LPA and serum on focal adhesion and stress fiber
formation are mediated by Rho (62), although the exact
signaling steps that lead to Rho activation downstream of LPA have not
yet been elucidated. The conversion from the GDP-bound form of Rho to
the GTP-bound form is regulated by two classes of protein factors: Rho
GDI and GNEFs (25). In unstimulated cells, Rho GDI binds and
prevents guanine nucleotide exchange on Rho as well as maintaining this
GTPase in the cytoplasm (1, 7). Upon stimulation by serum or
LPA, GNEFs, such as Dbl or Lbs, stimulate GTP exchange on Rho, which
dissociates from Rho GDI and becomes translocated to the membrane
fraction (7). A growing family of 15 or more proteins,
including Ost, faciogenital dysplasia protein, Isc, Abr, Bcr, Tiam-1,
and Vav, possess Dbl homology (DH) domains and may act as GNEFs for Rho
family GTPases (10, 20). All of these proteins also contain
pleckstrin homology domains, which bind to inositol phospholipids and
are required for membrane targeting and guanine nucleotide exchange
activity (79). The activities of GNEFs may also be modulated
by tyrosine phosphorylation, since Lck, a member of the Src family of
tyrosine kinases, can tyrosine phosphorylate and activate Vav, a GNEF
for Rho GTPases (14, 24). It is not yet clear, however,
whether tyrosine phosphorylation is used as a strategy for activation
of other GNEFs for Rho family GTPases. Our results suggest that the
activity of one of these upstream regulators of Rho, Rho GDI or a GNEF,
is controlled by v-Crk. Previously, we have shown that v-Crk expression
results in sustained growth factor-induced mitogen-activated protein
kinase (MAPK) activity in PC12 cells (70) and that this
effect is dependent on an intact SH3 domain of v-Crk. We have suggested
that v-Crk binding to SOS, a GNEF for Ras, through its SH3 domain leads
to increased activity of Ras and MAPK activation downstream of Ras. Through this domain, v-Crk also binds C3G, which was shown to be a GNEF
for Rap-1 (23, 68). Results by Tanaka et al. have shown that
C3G augments the v-Crk-induced activation of JNK and that this pathway
leads to cellular transformation (69). It remains to be
determined whether C3G plays any role in Rho activation or whether C3G
overexpression induces flattening or stress fiber formation in our
system. It is possible that v-Crk also binds a yet unknown GNEF for Rho
and leads to sustained activation of Rho and its downstream effectors.
However, to date, none of the cellular proteins that bind to the CrkSH3
domain, SOS, C3G, EPS15, DOCK180, Abl, or P13-kinase (6),
contain DH domains, and thus none are obvious candidates for a direct
Rho GNEF.
Tyrosine kinases were found to be required at signaling steps both
upstream and downstream of Rho, since treatment of cells with a
tyrosine kinase inhibitor, tryphostin, blocks Rho activation specifically at an upstream step (57). In contrast, another tyrosine kinase inhibitor, genistein, inhibits focal adhesion assembly
and stress fiber formation downstream of activated Rho (61).
Introduction of activated forms of Rho into cells results in increased
tyrosine phosphorylation of several cytoskeletal proteins, such as
paxillin, FAK, and p130cas (18, 65).
As suggested for focal adhesion assembly, this finding can be explained
by Rho-induced acto-myosin contraction and resulting adhesion complex
clustering (13). Clustering of integrin-bound complexes
would bring tyrosine kinases within these complexes into close
proximity and result in their trans-phosphorylation and
activation. Currently, it is believed that GTP binding of Rho leads to
acto-myosin contraction through activation of ROCKs, one of which
phosphorylates and inactivates a myosin light-chain phosphatase
(36). Increased phosphorylation of myosin light chain
correlates with increased acto-myosin contraction and precedes the
formation of stress fibers and focal adhesions (13). Also, it has recently been shown that overexpression of p160ROCK
can directly promote stress fiber formation and focal adhesion assembly
in fibroblasts and HeLa cells (3, 32). Rho in its GTP-bound
form also binds and activates a PIP5-kinase, resulting in increased
production of PI(4,5)P2 (60). PIP2,
in turn, removes barbed end-capping proteins from actin filament ends,
allowing filament elongation and an increase in the level of
polymerized actin (27). Also, by inducing a conformational
change in vinculin, PIP2 exposes binding sites for talin
and actin on vinculin (21), further promoting
actin-containing adhesion complex assembly. We found that the
activation levels of p160ROCK and a PIP5-kinase in
v-Crk-expressing PC12 cells are increased simultaneously, suggesting
that v-Crk may function to control both of these regulators of actin
cytoskeleton downstream of Rho.
In Saccaromyces cerevisiae, a scaffolding protein, Ste5p, is
important during the mating response to pheromones in linking the MAPK
module which controls transcriptional activation to the actin
cytoskeleton-regulatory module which controls polarized morphogenesis
(41). Ste5p is suggested to spatially restrict these
signaling components, which also play a role in pseudohyphal growth,
providing specificity for the mating response. The two modules that are
brought together by Ste5p comprise the Rho-like small GTPase Cdc42p, a
GNEF for this GTPase, Cdc24p, as well as the Ste20p family of
serine/threonine kinases, which are homologs of mammalian PAKs, an
SH3-containing protein Bem1p, actin, and yeast MAPK homologs. It is
possible that v-Crk serves an analogous scaffold function in mammalian
cells to spatially link Rho-dependent actin signaling to the tyrosine
kinase signaling during focal adhesion assembly, since the v-Crk SH2
domain binds substrates of the FAK and Src family of tyrosine kinases,
paxillin, and p130cas. Paxillin and
p130cas in turn bind other focal adhesion
proteins, including FAK, vinculin,
-actinin, talin, and integrins
(26, 53). Furthermore, we have recently shown that in
fibroblasts, v-Crk potentiates phosphotyrosine-dependent signaling
within focal adhesions, which could serve as nucleation sites for
signaling proteins such as Grb2, Src, Nck, and PI(3)-kinase (64). In the presence of v-Crk, this cytoskeletal complex
might therefore be placed in the proximity of regulators of actin, such as PIP(5)-kinase or p160ROCK, which are controlled by Rho.
In v-Crk-expressing PC12 cells, both vinculin and paxillin localize to
focal adhesions that look similar to the transitory-type focal
adhesions described by Bershadsky et al. in quail embryo fibroblasts
(5). Although these adhesions are seen preferentially at the
cell periphery and the associated actin fibers are thin, they are
clearly distinct from focal complexes, which do not associate with
actin fibers and are formed downstream of Rac activation.
We detected that expression of v-Crk leads to an increase in the amount
of FAK protein expression in PC12 cells. This may be due to
positive-feedback signals to the nucleus which originate from adhesion
complexes; conversely, degradation of FAK may be slower in these cells.
We are currently trying to distinguish between these two possibilities.
Our results suggest that until a certain threshold level of FAK is
reached, v-Crk-expressing PC12 cells do not acquire a flattened
phenotype in serum. This phenotypic conversion also correlates with
increased amounts of specific adhesion complex proteins such as
paxillin,
3-integrin, and a higher-molecular-weight form
of
1-integrin, although we do not know their precise
role during cell flattening. Recent studies have shown that aggregation
of FAK, by fusion to the ectodomain of CD2, causes constitutive
activation and accelerates the spreading of MDCK cells on collagen
(19). Activated FAK also confers resistance to a type of
apoptosis called aniokis, which occurs when cells detach from
extracellular matrix (30), and, as shown here, V15F cells
that display upregulation of FAK are highly resistant to apoptosis
during serum withdrawal. An interesting question is how two GTPase (Ras
and Rho)-dependent signals are spatially and temporally coordinated at
the level of v-Crk in PC12 cells, since both signaling cascades seem to
be potentiated by this protein. Our previous work suggests that
coupling of sustained Ras and MAPK activation to tyrosine kinase
signals is critical for potentiated differentiation in v-Crk-expressing
PC12 cells (70). However, facilitation of neurite elongation
does not become obvious in V15F when these cells are stimulated with
NGF; instead, a twofold isotropic enlargement in their mean surface
area is observed. Once activation of Rho is suppressed by serum
withdrawal or C3 toxin pretreatment, the cell soma becomes round and
individual axons are formed in response to NGF. Also, the initial stage
of axon formation and elongation is more rapid in these cells than in
wild-type PC12 cells, as we described previously (28).
Hence, in V15F cells, activation of Rho signals may counteract
Ras-activated signals, which are required for NGF-induced
differentiation. In contrast to wild-type PC12 cells, in which Rho
activation blocks neurite outgrowth by inducing growth cone collapse,
differentiation is masked in v-Crk cells by increased flattening after
NGF treatment.
Our present assays did not determine which integrins are responsible
for accumulation of these focal adhesions in v-Crk-expressing PC12
cells. Previously it was shown that the ligand specificities of
integrins determine their distribution to focal adhesions
(16). When the cells are plated on a specific extracellular
matrix molecule, the integrin receptors specific for that molecule are
seen to be driven into focal adhesions that form within these cells.
Recently, it has been shown that a short sequence of the
subunit of
the integrin dimer may determine substrate specificity and hence
distribution to focal adhesions (67). In our assays, we
could not detect any of the integrin subunits we tested within focal
adhesions of v-Crk cells which were plated in fibronectin- and
vitronectin-containing serum. Also, this result was not affected by
plating cells on various other substrata. Previously,
1
1- and
3
1-integrins, which recognize different
domains in laminin, were shown to be expressed in PC12 cells
(73). Among these,
1
1-integrin
is variably expressed in different strains of PC12 cells, and its expression can be induced by NGF treatment (78). Indeed, in PC12 strains, which we used in this study and which were constructed to
express v-Crk protein,
1
1-integrin
expression was much lower than in another PC12 strain (Fig. 10, compare
lanes 2 and 8). We did not detect any increase in
1
1-integrin levels in flat v-Crk cells.
Immunofluorescent staining with MAb 3A3 (against the
1 subunit) as well as with anti-
1-integrin subunit
antibody showed localization of
1-integrins, including
1
1-integrin, in small punctate adhesions
along the cell periphery. Although an increase in
3
1-integrin levels may be a prerequisite
for the cell-flattening response to serum, we could not detect
3
1-integrin in focal adhesions even when
cells were plated on laminin, suggesting that this integrin does not
take part in the formation of these adhesions in v-Crk cells. We could
not detect any
5
1-integrin, which binds to fibronectin and was previously shown to localize to focal adhesions in fibroblasts, in PC12 cells. In V15F cells,
v-integrin
staining was seen within small, granular adhesion complexes throughout the ventral cell surface. Hence, our results suggest that a currently unidentified integrin may be involved in the formation of these focal
adhesions in v-Crk cells.
In summary, we have presented evidence that v-Crk activates the Rho
pathway in PC12 cells to induce stress fibers and focal adhesion
biogenesis following serum or LPA stimulation. Formation